5068792026-04-235068792026-04-232026-04-235068792026-04-23in-capmkt:FinancialYear1Member5068792026-04-23in-capmkt:FinancialYear2Member5068792026-04-23in-capmkt:FinancialYear3Member5068792026-04-232026-04-23in-capmkt:FinancialYear1Member5068792026-04-232026-04-23in-capmkt:FinancialYear2Member5068792026-04-232026-04-23in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure506879Gujarat Themis Biosyn LimitedGUJTHEMNAINE942C01045NewAcquisition (including agreement to acquire)false2026-04-2323:21:002026-04-23Gujarat Themis Biosyn limitedListed Entity (self)SANOFI000falsefalsetruePharma IndustryThis acquisition represents a significant step in GTBL’s strategy to strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realizations across the value chain.YesAntitrust & foreign direct investment approvalsfalse31/12/2026Cash17400000000Euro 158 million0000Acquisition of 13 established branded generic products with a strong presence across more than 55 countries, including Europe, the Middle East and Africa from the Seller, Sanofi, French holding Company of the Sanofi group headquartered in Paris. The acquisition will include marketing authorizations, brands, regulatory dossiers, and inventory and associated commercial rights. The transaction does not involve the acquisition of legal entity, transfer of manufacturing facilities or employees, making it a capital-efficient and asset-light expansion for the Company. 2024-202568280000002023-202473787000002022-20237268500000FranceThe acquisition is of 13 branded generic products . The Company has not acquired any entity therefore only relevant information has been provided.